Pure Global

Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome - Trial NCT05867693

Access comprehensive clinical trial information for NCT05867693 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Roma La Sapienza and is currently Recruiting. The study focuses on Irritable Bowel Syndrome. Target enrollment is 70 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05867693
Recruiting
dietary supplement
Trial Details
ClinicalTrials.gov • NCT05867693
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome
Palmitoylethanolamide and Polydatin in Pediatric Irritable Bowel Syndrome: a Randomized Controlled Trial

Study Focus

Irritable Bowel Syndrome

palmithoylethanolamide/polydatin

Interventional

dietary supplement

Sponsor & Location

University of Roma La Sapienza

Roma, Italy

Timeline & Enrollment

N/A

Apr 19, 2023

Apr 19, 2024

70 participants

Primary Outcome

Change in the abdominal pain symptoms

Summary

This will be a randomised, double-blind, placebo-controlled, parallel-arm trial, designed to
 study the efficacy and safety of co-micronised palmithoylethanolamide/polydatin in pediatric
 patients ( 10 years) with Irritable bowel syndrome (IBS)

ICD-10 Classifications

Irritable bowel syndrome
Other and unspecified irritable bowel syndrome
Irritable bowel syndrome with mixed bowel habits [IBS-M]
Irritable bowel syndrome with predominant constipation [IBS-C]
Irritable bowel syndrome with predominant diarrhoea [IBS-D]

Data Source

ClinicalTrials.gov

NCT05867693

Non-Device Trial